IRWD / Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q1 2022 Results - Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-g more_horizontal

Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the more_horizontal

Ironwood Pharmaceuticals specializes in the development and commercialization of drugs for gastrointestinal diseases, with a focus on conditions like more_horizontal

Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues. more_horizontal

Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the com more_horizontal

Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio. more_horizontal

Investors cheered the gastrointestinal treatment specialist's latest asset buy. This, despite the fact that it's paying a more-than 40% premium, accor more_horizontal

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Matt Roache - Director of In more_horizontal